Login to Your Account



RA Drug Clazakizumab Gives a Boost to BMS

By Marie Powers
Staff Writer

Tuesday, October 29, 2013
The humanized anti-interleukin (IL)-6 monoclonal antibody (MAb) clazakizumab passed muster in its first major study, a dose-ranging Phase IIb in 418 adults with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription